<unk>  <unk> -DHLNG) is an active metabolite of the progestin levonorgestrel which is formed by<unk> -reductase. It has about one-third of the affinity of levonorgestrel for the progesterone receptor. In contrast to levonorgestrel, the compound has both progestogenic and antiprogestogenic activity, and hence has a selective progesterone receptor modulator-like profile of activity. This is analogous to the case of norethisterone and<unk> -dihydronorethisterone. In addition to the progesterone receptor,<unk> -DHLNG interacts with the androgen receptor. It has similar affinity for the androgen receptor relative to levonorgestrel (34.3% of that of metribolone for levonorgestrel and 38.0% of that of metribolone for<unk> -DHLNG), and has androgenic effects similarly to levonorgestrel and testosterone.<unk> -DHLNG is further transformed into 3α,5α- and 3β,5α-, which bind weakly to the estrogen receptor (0.4 to 2.4% of the of ) and have weak estrogenic activity. These metabolites are considered to be responsible for the weak estrogenic activity of high doses of levonorgestrel.
5α-Dihydrolevonorgestrel
Chloroethynylnorgestrel
Levonorgestrel
Cloxestradiol acetate
Lipoidal estradiol
Ethyltestosterone
Desoxymethyltestosterone
Hydroxyprogesterone acetate